TY  - JOUR
AU  - Ehret, Felix
AU  - Wolfgang, Josy
AU  - Allwohn, Luisa
AU  - Onken, Julia
AU  - Wasilewski, David
AU  - Roohani, Siyer
AU  - Oertel, Joachim
AU  - Zips, Daniel
AU  - Kaul, David
TI  - Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation.
JO  - Clinical and translational radiation oncology
VL  - 42
SN  - 2405-6308
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2023-01517
SP  - 100653
PY  - 2023
AB  - Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation.GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis.A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80
KW  - Glioblastoma (Other)
KW  - IDH (Other)
KW  - Isocitrate Dehydrogenase (Other)
KW  - Radiation Necrosis (Other)
KW  - Radionecrosis (Other)
KW  - Radiotherapy (Other)
KW  - Re-irradiation (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37502699
C2  - pmc:PMC10369398
DO  - DOI:10.1016/j.ctro.2023.100653
UR  - https://inrepo02.dkfz.de/record/277806
ER  -